Annual Report 2025 Active Biotech AB (publ)

ACTIRegulatory press release01.04.2026 klo 10.30

Active Biotech (NASDAQ Stockholm:ACTI) announces today that the Annual Report 2025 now is available for download at www.activebiotech.com.

The Annual Report will only be digitally distributed.

“Building on progress in 2025, the coming year will focus on the tasquinimod clinical studies in myelofibrosis and intensified business development for laquinimod,” says Active Biotech CEO Helén Tuvesson.

About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that develops first-in-class immunomodulatory treatments for oncology and immunology indications with a high unmet medical need and significant commercial potential. The company's core focus is on the development of tasquinimod in myelofibrosis, a rare blood cancer, where clinical proof-of-concept studies have been initiated. Laquinimod is in development for the treatment of non-infectious uveitis. A clinical phase I program with a topical ophthalmic formulation has been performed to support phase II development together with a partner. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.